Eagle Pharmaceuticals, Inc. (EGRX)
After hours:
| Previous close | 26.69 |
| Open | 26.99 |
| Bid | 23.00 x 1100 |
| Ask | 43.40 x 1100 |
| Day's range | 26.50 - 27.50 |
| 52-week range | 23.87 - 52.22 |
| Volume | |
| Avg. volume | 161,079 |
| Market cap | 350.537M |
| Beta (5Y monthly) | 0.92 |
| PE ratio (TTM) | 9.79 |
| EPS (TTM) | 2.75 |
| Earnings date | 08 May 2023 - 12 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 32.00 |
- Zacks
Eagle Pharmaceuticals (EGRX) Beats Q4 Earnings and Revenue Estimates
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 41.03% and 2.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results
• Q4 2022 net income was $0.63 per basic and $0.62 per diluted share and adjusted non-GAAP net income was $1.11 per basic and $1.10 per diluted share1 • Total revenue for Q4 2022 was $60.7 million, compared to $42.3 million in Q4 2021 • FY 2022 net income was $2.76 per basic and $2.73 per diluted share and adjusted non-GAAP net income was $7.87 per basic and $7.79 per diluted share1 • FY 2022 revenue was $316.6 million compared to $171.5 million in FY 2021 • FY 2022 net sales of PEMFEXY® totaled
- GlobeNewswire
Eagle Pharmaceuticals to Present at the Barclays Global Healthcare Conference
WOODCLIFF LAKE, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference, in Miami, FL, as follows: Date:Wednesday, March 15, 2023 Time:2:35pm ETWebcast:Click Here To schedule a 1x1 meeting, please contact your Barclays representative. About Eagle Pharmaceutica
